Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbbVie HCV virologic failure retreatment study with ABT-450/ritonavir + ABT-267 + peginterferon alfa-2a + ribavirin
2011-005393-32Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paritaprevir, ritonavir, glecaprevir, peginterferon alfa-2a and ribavirin in chronic hepatitis C (CHC), sponsored by AbbVie Inc. Primary endpoint: SVR12actual. Started May 2012; status: completed.
02
Drugs
paritaprevirritonavirglecaprevirpeginterferon alfa-2aribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2011-005393-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005393-32.